Core Viewpoint - The announcement by China Securities Index Co., Ltd. on January 6 indicates adjustments to the sample stocks of the CSI 1000, CSI 500, and CSI A500 indices, effective after market close on January 9, 2026 [1] Group 1: Index Adjustments - Chipone Technology is added to the CSI 500 index [1] - Mingyue Lens is added to the CSI 1000 index [1] - BGI Genomics is added to the CSI A500 index [1] Group 2: Exclusions from Indices - ST Renfu is removed from both the CSI 500 and CSI A500 indices [1] - Chipone Technology is removed from the CSI 1000 index [1]

Core Viewpoint - The company has received approval for clinical trials of HW221043 tablets, a new molecular entity aimed at treating advanced solid tumors, marking a significant step in its drug development process [1][2]. Group 1: Drug Development - The drug HW221043 is classified as a Class 1 chemical drug and is intended for clinical trials in patients with advanced solid tumors [1]. - The total research and development investment for HW221043 has reached approximately 24 million RMB [2]. - The company plans to initiate clinical research following the receipt of the clinical trial approval and will submit trial data to the National Medical Products Administration for production approval after completion [2]. Group 2: Regulatory Approval - The National Medical Products Administration has granted the clinical trial approval for HW221043, confirming that it meets the necessary registration requirements [1]. - The approval was based on the review conducted on October 29, 2025, allowing the drug to proceed with clinical trials [1].

Group 1: Regulatory Developments - The National Healthcare Security Administration (NHSA) is seeking public opinions on the draft guidelines for the real-world comprehensive value assessment of medical services, aiming to establish a unified evaluation system across the country [1] - CanSino Biologics has received approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine, which targets major circulating serotypes and is intended for individuals aged 2 months and older [2] - Merck has announced that its breakthrough therapy, Sotatercept, has been approved in China for treating adult patients with pulmonary arterial hypertension (PAH), based on data from the STELLAR Phase III clinical trial [3] - ST. Renfu has received approval for clinical trials of HW221043 tablets, intended for the treatment of advanced solid tumors, with no similar drugs currently approved in the market [4] - Heng Rui Medicine has received approval for clinical trials of HRS-4357 injection and HRS-5041 tablets, aimed at treating PSMA-positive prostate cancer [5] Group 2: Market Activities - Shenzhou Cell has received approval from the China Securities Regulatory Commission for its application to issue stocks to specific investors [6] - Tianchen Medical has signed a strategic cooperation agreement with Inspur Digital Technology to promote innovation in medical intelligent manufacturing and robotics [7] - Zhonghong Medical's subsidiary has participated in a bidding project for centralized procurement of medical consumables, with some products expected to be selected, enhancing market presence [8] - Yifan Pharmaceutical's subsidiary has signed an exclusive agreement with Shangde Yaoyuan for the ACT001 drug, involving a total payment of 1 billion yuan [9] - Yijiahe is exploring the application of "brain-computer interface + embodied intelligent robots" technology in smart healthcare scenarios, having signed a strategic cooperation agreement with Mairande [10]

Group 1 - Ugreen Technology expects a net profit of 653 million to 733 million yuan for 2025, representing a year-on-year growth of 41.26% to 58.56% [1] - SenTai Co. plans to invest no more than 140 million yuan to establish a production base in Vietnam [2] - Muyuan Foods reported a December 2025 sales revenue of 9.667 billion yuan from commodity pigs, a year-on-year decline of 36.06% [3] Group 2 - Pumen Technology has received a medical device registration certificate for a quality control product used in various cancer markers [4] - Heng Rui Medicine's subsidiary has received approval for clinical trials of two injection drugs targeting obesity [5] - Quartz Co. was fined 2.7 million yuan for commercial secret infringement by its subsidiary [6] Group 3 - Chifeng Gold expects a net profit of 3 billion to 3.2 billion yuan for 2025, an increase of approximately 70% to 81% year-on-year [7] - Fulong Technology has terminated the transfer of 82.0969 million shares [8] - Senba Sensor's actual controller has released the pledge of 16.48 million shares [9] Group 4 - Hanma Technology reported a cumulative truck sales increase of 58.45% for 2025 [12] - Guankang Clean won a bid for a special procurement project worth 157 million yuan [14] - Defu Technology signed a cooperation agreement for high-end copper foil supply with a leading CCL company [15] Group 5 - Tianchen Medical signed a strategic cooperation agreement with Inspur Digital Technology [16] - CanSino received approval for clinical trials of a 24-valent pneumococcal polysaccharide conjugate vaccine [17] - Yipin Hong's subsidiary received approval for a supplementary application for oseltamivir phosphate capsules [19] Group 6 - Taotao Vehicle expects a net profit of 800 million to 850 million yuan for 2025, a year-on-year increase of 85.50% to 97.10% [20] - Yutong Bus reported a cumulative sales increase of 5.54% for 2025 [21] - Kingoo Co. received a notification from VinFast to supply automotive wheel products [22] Group 7 - ST Renfu's subsidiary received approval for clinical trials of a new drug for late-stage solid tumors [23] - Nanxing Co. expects a net profit of 90 million to 120 million yuan for 2025, reversing a loss from the previous year [24] - Jinrui Mining's subsidiaries will undergo routine maintenance starting January 5, 2026 [25] Group 8 - Changjiang Power reported a 3.82% increase in total power generation for its six hydropower stations in 2025 [26] - David Medical's subsidiary received a medical device registration certificate for an electronic endoscope image processor [28] - Guiguan Power reported a 26.68% increase in cumulative power generation for 2025 [29] Group 9 - ShenNan Electric's subsidiary won a project worth 208 million USD for a power plant operation service [30] - ST Kaiyuan's major shareholder's shares will be auctioned [31] - Jiecheng Co.'s major shareholder's shares have been auctioned [32] Group 10 - Tongbao Energy's wind power project has begun generating electricity [33] - Xusheng Group received an order worth 7.8 billion yuan from a North American EV manufacturer [34] - Qianli Technology reported a 154.08% increase in December 2025 electric vehicle production [35] Group 11 - Chint Electric plans to issue H-shares and list on the Hong Kong Stock Exchange [36][37] - Whirlpool expects a net profit increase of approximately 150% for 2025 [38] - Yongjie New Materials signed a 2 billion yuan aluminum alloy procurement contract [39]

Core Viewpoint - ST Renfu (600079) announced the approval of its drug HW221043 for clinical trials, marking a significant step in its development of a new treatment for advanced solid tumors [1] Group 1: Company Developments - ST Renfu's wholly-owned subsidiary, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., received the clinical trial approval notice from the National Medical Products Administration for HW221043 [1] - HW221043 is a new molecular entity developed independently by the company, with no similar drugs approved for market in China or abroad [1] - The total research and development investment for HW221043 has reached approximately 24 million yuan [1]

Group 1 - The fentanyl concept index rose by 4.74%, ranking 6th among concept sectors, with 8 stocks increasing in value, including Botao Bio which hit a 20% limit up [1] - The leading stocks in the fentanyl sector included Dongfang Bio, Lingrui Pharmaceutical, and ST Renfu, which rose by 5.12%, 4.88%, and 2.26% respectively [1] Group 2 - The fentanyl concept sector saw a net inflow of 55 million yuan, with ST Renfu leading the inflow at 69.89 million yuan, followed by Guoyao Shares, Guoyao Modern, and Lingrui Pharmaceutical [2] - The net inflow ratios for ST Renfu, Guoyao Modern, and Guoyao Shares were 14.70%, 7.69%, and 5.96% respectively, indicating strong interest from major funds [3]

Core Viewpoint - ST Renfu (600079) has received approval from the National Medical Products Administration for the clinical trial of HW221043 tablets, a new molecular entity aimed at treating advanced solid tumors, with no similar drugs approved in the market to date [1]. Group 1: Company Developments - The wholly-owned subsidiary of ST Renfu, Hubei Biopharmaceutical Industry Technology Research Institute Co., Ltd., has been granted the clinical trial approval for HW221043 tablets [1]. - HW221043 tablets represent a self-developed new molecular entity by the company [1]. - The total research and development investment for HW221043 tablets has reached approximately 24 million yuan [1]. Group 2: Market Context - There are currently no similar drugs approved for market use, indicating a potential unique position for HW221043 in the treatment of advanced solid tumors [1].

关于 HW221043 片获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 人福医药集团股份公司（以下简称"公司"）全资子公司湖北生物医药产业技术研 究院有限公司（以下简称"研究院有限公司"）近日收到国家药品监督管理局核准签发 的HW221043片的《药物临床试验批准通知书》，现将相关情况公告如下： 一、药品名称：HW221043片 二、剂型：片剂 证券代码：600079 证券简称：ST 人福 编号：临 2026-001 人福医药集团股份公司 四、注册分类：化学药品1类 五、申请人：湖北生物医药产业技术研究院有限公司 六、审批结论：经审查，2025年10月29日受理的HW221043片符合药品注册的有关 要求，同意本品单药在晚期实体瘤患者中开展临床试验。 HW221043 片拟用于晚期实体瘤的治疗，是由公司自主研发的新分子实体化合物， 目前国内外暂无同类药物获批上市。截至目前，HW221043 片累计研发投入约为 2,400 万元人民币。 根据我国药品注册相关的法律法规要求，研究院有限公司在收到 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HW221043 tablets in patients with advanced solid tumors, marking a significant step in its drug development efforts [1] Group 1: Drug Development - HW221043 tablets are intended for the treatment of advanced solid tumors and are a new molecular entity developed by the company [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for HW221043 tablets has reached approximately 24 million RMB [1]

Core Viewpoint - ST Renfu (600079.SH) has received approval from the National Medical Products Administration for its drug HW221043, which is intended for the treatment of advanced solid tumors and is a new molecular entity developed by the company [1] Group 1: Drug Development - HW221043 is a new molecular compound developed independently by the company [1] - There are currently no similar drugs approved for market use domestically or internationally [1] - The total research and development investment for HW221043 has reached approximately 24 million RMB [1]